SI1900362T1 - Alfa-aminoamide derivatives useful in the treatment of addictive disorders - Google Patents
Alfa-aminoamide derivatives useful in the treatment of addictive disordersInfo
- Publication number
- SI1900362T1 SI1900362T1 SI200531224T SI200531224T SI1900362T1 SI 1900362 T1 SI1900362 T1 SI 1900362T1 SI 200531224 T SI200531224 T SI 200531224T SI 200531224 T SI200531224 T SI 200531224T SI 1900362 T1 SI1900362 T1 SI 1900362T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- alfa
- addictive disorders
- derivatives useful
- aminoamide derivatives
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Certain ±-aminoamide derivatives for use in the treatment of addictive disorders are disclosed. The compounds of this invention are able to reduce or even stop the symptoms of addictive disorders substantially without side effects.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04009532A EP1588704A1 (en) | 2004-04-22 | 2004-04-22 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
EP07022078A EP1900362B1 (en) | 2004-04-22 | 2005-04-19 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1900362T1 true SI1900362T1 (en) | 2011-03-31 |
Family
ID=34924693
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200530430T SI1737438T1 (en) | 2004-04-22 | 2005-04-19 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome |
SI200531224T SI1900362T1 (en) | 2004-04-22 | 2005-04-19 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200530430T SI1737438T1 (en) | 2004-04-22 | 2005-04-19 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome |
Country Status (26)
Country | Link |
---|---|
US (2) | US8445513B2 (en) |
EP (3) | EP1588704A1 (en) |
JP (1) | JP5020069B2 (en) |
KR (2) | KR101238377B1 (en) |
CN (1) | CN1942179B (en) |
AT (2) | ATE405256T1 (en) |
AU (1) | AU2005235428B2 (en) |
BR (2) | BRPI0509976B8 (en) |
CA (1) | CA2563674C (en) |
CY (2) | CY1108494T1 (en) |
DE (2) | DE602005009162D1 (en) |
DK (2) | DK1900362T3 (en) |
ES (2) | ES2313330T3 (en) |
HK (1) | HK1099216A1 (en) |
HR (2) | HRP20080593T3 (en) |
IL (1) | IL178732A (en) |
ME (2) | ME02324B (en) |
MX (1) | MXPA06012163A (en) |
NO (2) | NO337900B1 (en) |
NZ (1) | NZ550664A (en) |
PL (2) | PL1737438T3 (en) |
PT (2) | PT1737438E (en) |
RS (2) | RS50667B (en) |
RU (1) | RU2403030C2 (en) |
SI (2) | SI1737438T1 (en) |
WO (1) | WO2005102300A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
SI1423168T1 (en) | 2001-09-03 | 2006-06-30 | Newron Pharm Spa | Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
KR101233711B1 (en) * | 2003-08-25 | 2013-02-18 | 뉴론 파마슈티칼즈 에스. 피. 에이. | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
JP5319920B2 (en) * | 2004-09-10 | 2013-10-16 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | Use of (halobenzyloxy) benzylamino-propanamide for the manufacture of a medicament active as a sodium and / or calcium channel selective modulator |
US20060173074A1 (en) * | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
SI1963280T1 (en) | 2005-12-22 | 2016-02-29 | Newron Pharmaceuticals S.P.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
LT2474521T (en) * | 2006-06-19 | 2016-11-25 | Newron Pharmaceuticals S.P.A. | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them |
GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
EA018195B1 (en) | 2007-06-15 | 2013-06-28 | Ньюрон Фармасьютикалс С.П.А. | Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
DK2229351T3 (en) | 2007-12-11 | 2018-01-22 | Newron Pharm Spa | PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY |
KR101500962B1 (en) * | 2007-12-19 | 2015-03-10 | 뉴론 파마슈티칼즈 에스. 피. 에이. | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders |
EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
MX342697B (en) | 2010-04-27 | 2016-10-10 | Newron Pharmaceuticals S P A * | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers. |
US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
CN114667963B (en) * | 2020-12-24 | 2024-04-26 | 中国科学院脑科学与智能技术卓越创新中心 | Device for evaluating drug addiction of non-human primate |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
US4049663A (en) * | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
FR2480747A1 (en) * | 1980-04-17 | 1981-10-23 | Roques Bernard | AMINO ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4970200A (en) * | 1988-03-01 | 1990-11-13 | Schering Aktiengesellschaft | Agent for treatment of Parkinson's disease |
IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical compositions containing n-phenylalkyl substituted alpha-amino carboxamide derivatives, some such novel compounds and their preparation |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
EP0520325A1 (en) * | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Use of monoamine oxidase-B-inhibitors for the prevention and treatment of withdrawal symptoms after alcohol and drug abuse |
GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
EP0828513B1 (en) * | 1995-05-26 | 2004-01-21 | Pfizer Inc. | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
WO1997000511A1 (en) | 1995-06-17 | 1997-01-03 | Baumann Guenter | Disc-shaped member |
GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
WO1999035215A2 (en) | 1998-01-12 | 1999-07-15 | Deborah Wenzel | An additive composition also used as a fuel composition comprising water soluble alcohols |
FI109453B (en) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Pharmaceutical composition |
AU1359801A (en) * | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
WO2001041763A1 (en) * | 1999-12-10 | 2001-06-14 | University Of Cincinnati | Treatment of addiction disorders |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
CA2450315A1 (en) * | 2001-06-13 | 2002-12-19 | The Regents Of The University Of Michigan | Dopamine receptor ligands and therapeutic methods based thereon |
WO2003099763A1 (en) * | 2002-05-29 | 2003-12-04 | F. Hoffmann-La Roche Ag | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors |
WO2004000742A2 (en) | 2002-06-24 | 2003-12-31 | Rockwool International A/S | Process and apparatus for controlling mineral wool production using a cascade rotor |
US6900354B2 (en) * | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
AR044007A1 (en) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE |
JP2005060370A (en) * | 2003-07-25 | 2005-03-10 | Kyowa Hakko Kogyo Co Ltd | Medicinal composition |
EP1524267A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
-
2004
- 2004-04-22 EP EP04009532A patent/EP1588704A1/en not_active Withdrawn
-
2005
- 2005-04-19 CN CN2005800118905A patent/CN1942179B/en active Active
- 2005-04-19 AT AT05736365T patent/ATE405256T1/en active
- 2005-04-19 PL PL05736365T patent/PL1737438T3/en unknown
- 2005-04-19 EP EP05736365A patent/EP1737438B1/en active Active
- 2005-04-19 AT AT07022078T patent/ATE494890T1/en active
- 2005-04-19 SI SI200530430T patent/SI1737438T1/en unknown
- 2005-04-19 RS RSP-2008/0531A patent/RS50667B/en unknown
- 2005-04-19 US US11/578,988 patent/US8445513B2/en active Active
- 2005-04-19 PL PL07022078T patent/PL1900362T3/en unknown
- 2005-04-19 NZ NZ550664A patent/NZ550664A/en unknown
- 2005-04-19 JP JP2007508825A patent/JP5020069B2/en active Active
- 2005-04-19 KR KR1020127003440A patent/KR101238377B1/en active IP Right Grant
- 2005-04-19 ES ES05736365T patent/ES2313330T3/en active Active
- 2005-04-19 BR BRPI0509976A patent/BRPI0509976B8/en active IP Right Grant
- 2005-04-19 MX MXPA06012163A patent/MXPA06012163A/en active IP Right Grant
- 2005-04-19 ME MEP-2016-18A patent/ME02324B/en unknown
- 2005-04-19 DE DE602005009162T patent/DE602005009162D1/en active Active
- 2005-04-19 DK DK07022078.5T patent/DK1900362T3/en active
- 2005-04-19 ES ES07022078T patent/ES2357559T3/en active Active
- 2005-04-19 BR BR122020004541-8A patent/BR122020004541B1/en active IP Right Grant
- 2005-04-19 DE DE602005025941T patent/DE602005025941D1/en active Active
- 2005-04-19 PT PT05736365T patent/PT1737438E/en unknown
- 2005-04-19 DK DK05736365T patent/DK1737438T3/en active
- 2005-04-19 KR KR1020067021748A patent/KR101195819B1/en active IP Right Grant
- 2005-04-19 AU AU2005235428A patent/AU2005235428B2/en active Active
- 2005-04-19 EP EP07022078A patent/EP1900362B1/en active Active
- 2005-04-19 RU RU2006137079/15A patent/RU2403030C2/en active
- 2005-04-19 PT PT07022078T patent/PT1900362E/en unknown
- 2005-04-19 WO PCT/EP2005/004166 patent/WO2005102300A1/en active Application Filing
- 2005-04-19 ME MEP-2011-56A patent/ME01219B/en unknown
- 2005-04-19 SI SI200531224T patent/SI1900362T1/en unknown
- 2005-04-19 CA CA2563674A patent/CA2563674C/en active Active
- 2005-04-19 RS RS20110128A patent/RS51791B/en unknown
-
2006
- 2006-10-19 NO NO20064732A patent/NO337900B1/en unknown
- 2006-10-19 IL IL178732A patent/IL178732A/en active IP Right Grant
-
2007
- 2007-06-13 HK HK07106351.3A patent/HK1099216A1/en unknown
-
2008
- 2008-11-10 CY CY20081101279T patent/CY1108494T1/en unknown
- 2008-11-18 HR HR20080593T patent/HRP20080593T3/en unknown
-
2011
- 2011-03-04 CY CY20111100255T patent/CY1111656T1/en unknown
- 2011-03-30 HR HR20110230T patent/HRP20110230T1/en unknown
-
2013
- 2013-03-15 US US13/835,445 patent/US8697738B2/en active Active
-
2015
- 2015-07-27 NO NO20150971A patent/NO338870B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1900362T3 (en) | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | |
LUC00217I2 (en) | ||
HUS1900005I1 (en) | Improved nanobodies tm for the treatment of aggregation-mediated disorders | |
IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
IL191283A (en) | Compositions for the treatment of ophthalmic disorders | |
IL185016A0 (en) | Compounds for the treatment of proliferative disorders | |
ZA200700384B (en) | Hydantoin derivatives for the treatment of inflammatory disorders | |
TW200510301A (en) | Novel compounds | |
TW200510303A (en) | Novel compounds | |
EP1814535A4 (en) | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders | |
IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
WO2008011113A3 (en) | Thiadiazolidinone derivatives | |
ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
PT2366393E (en) | Roflumilast for the treatment of pulmonary hypertension | |
IL189524A0 (en) | Imidazole compounds for the treatment of neurological disorders | |
MXPA05011699A (en) | Agents for the treatment of lower abdominal disorders. | |
EP1890711A4 (en) | Compounds for treating or preventing amine oxidase related diseases or disorders | |
IL185653A (en) | Antibodoies which bind the stalk region of kim-1 | |
EP1937242A4 (en) | Methods and compositions for the treatment of neuropsychiatric and addictive disorders | |
ZA200800409B (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
WO2006060202A3 (en) | Imidazole derivatives for the treatment of psychiatric disorders | |
WO2006060201A3 (en) | Pyrazole derivatives for the treatment of psychiatric disorders |